DAFTAR PUSTAKA

1. Christopher J. Rapuano, J. Timothy Stout, Colin A. McCannel. Basic and Clinical Science Course, Section 10: Glaucoma. 2022nd–2023rd ed. anna AP, Boland MV GJ, editor. San Francisco: American Academy Of Ophthalmology.; 2022. 3–130 p.
2. Buccarello L, Dragotto J, Hassanzadeh K, Maccarone R, Corbo M, Feligioni M. Retinal ganglion cell loss in an ex vivo mouse model of optic nerve cut is prevented by curcumin treatment. Cell Death Discov. 2021;7(1):1–11.
3. Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis. Ophthalmology [Internet]. 2014;121(11):2081–90. Available from: http://dx.doi.org/10.1016/j.ophtha.2014.05.013
4. Pusdatin Kemenkes RI. InfoDatin Glaukoma 2019.pdf. 2019. p. 1–9.
5. Kementerian Kesehatan RI. Profil Kesehatan Indonesia 2014 [Internet]. Vol. 1227. 2014. 496 p. Available from: website: http://www.kemkes.go.id
6. Ariesti A, Herriadi D. Profile of Glaucoma at The Dr . M . Djamil Hospital Padang. J Kesehat Andalas. 2018;7(Supplement 1):34–7.
7. Pang IH, Clark AF. Inducible rodent models of glaucoma [Internet]. Vol. 75, Progress in Retinal and Eye Research. 2020. p. 100799. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1350946219300862
8. Petpaiboon T. The Pathophysiology, Diagnosis, and Possible Treatments of Glaucoma. Int J Surg Med [Internet]. 2022;4(4):1. Available from: http://www.ijsred.com/volume4/issue4/IJSRED-V4I4P54.pdf
9. Aslan M, Dogan S, Kucuksayan E. Oxidative stress and potential applications of free radical scavengers in glaucoma. Redox Rep. 2013;18(2):76–87.
10. Adornetto A, Rombolà L, Morrone LA, Nucci C, Corasaniti MT, BagettaG, et al. Natural Products: Evidence for Neuroprotection to Be Exploited in Glaucoma. Nutrients [Internet]. 2020 Oct 16;12(10):3158. Available from: https://www.mdpi.com/2072-6643/12/10/3158
11. Almasieh M, Wilson AM, Morquette B, Cueva Vargas JL, Di Polo A. The molecular basis of retinal ganglion cell death in glaucoma. Prog Retin Eye Res [Internet]. 2012;31(2):152–81. Available from: http://dx.doi.org/10.1016/j.preteyeres.2011.11.002
12. Zivkovic M, Dayanir V, Zlatanovic M, Zlatanovic G, Jaksic V, Jovanovic P, et al. Ganglion Cell-Inner Plexiform Layer Thickness in Different Glaucoma Stages Measured by Optical Coherence Tomography.Ophthalmic Res. 2018;59(3):148–54.
13. Madeira MH, Ortin-Martinez A, Nadal-Nícolas F, Ambrósio AF, Vidal-Sanz M, Agudo-Barriuso M, et al. Caffeine administration prevents retinal neuroinflammation and loss of retinal ganglion cells in an animal model of glaucoma. Sci Rep [Internet]. 2016;6(June). Available from: http://dx.doi.org/10.1038/srep27532
14. Madeira MH, Elvas F, Boia R, Gonçalves FQ, Cunha RA, Ambrósio AF, et al. Adenosine A2AR blockade prevents neuroinflammation-induced death

of retinal ganglion cells caused by elevated pressure. J Neuroinflammation. 2015 Dec;12(1):115.
15. Depaula J, Farah A. Caffeine consumption through coffee: Content in the beverage, metabolism, health benefits and risks. Beverages. 2019;5(2).
16. Aires ID, Boia R, Rodrigues-Neves AC, Madeira MH, Marques C, Ambrósio AF, et al. Blockade of microglial adenosine A 2A receptor suppresses elevated pressure-induced inflammation, oxidative stress, and cell death in retinal cells. Glia. 2019 May;67(5):896–914.
17. Adekeye A. Caffeine Improves Elevated IOP by modulating Oxido-inflammatory responses in Rat Models of Glaucoma. 2022;1–13. Available from: https://assets.researchsquare.com/files/rs-2128770/v1/026c196f-0749-441e-9627-c0b6f1cd4c85.pdf?c=1677075272
18. Christopher J. Rapuano J. Timothy Stout CAM. Basic and Clinical Science Course Section 2: Fundamentals and Principles of Ophthalmology. In: The American Academy of Ophthalmology. 2022nd–2023rd ed. San Francisco; 2022. p. 109–19.
19. Christopher J. Rapuano J. Timothy Stout CAM. 2022-2023 Basic and Clinical Science Course, Section 5: Neuro-Ophthalmology. In: The American Academy of Ophthalmology. San Francisco; 2023. p. 3–55.
20. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet [Internet]. 2004 May;363(9422):1711–20. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673604162570
21. Christopher J. Rapuano J. Timothy Stout CAM. Basic and Clinical Science Course, Section 12: Retina and Vitreous. In: The American Academy of Ophthalmology. 2022nd–2023rd ed. San Francisco; 2022. p. 5–19.
22. Schachat AP. Ryan ' s Retina Sixth Edition. 6th ed. USA; 2018.
23. Europe E, Asia C. Million 2050. 2020;2020.
26. Buccarello L, Dragotto J, Hassanzadeh K, Maccarone R, Corbo M, Feligioni M. Retinal ganglion cell loss in an ex vivo mouse model of optic nerve cut is prevented by curcumin treatment. Cell Death Discov [Internet]. 2021 Dec 15;7(1):394. Available from: https://www.nature.com/articles/s41420-021-00760-1
27. Saccà SC, Pulliero A, Izzotti A. The Dysfunction of the Trabecular Meshwork During Glaucoma Course. J Cell Physiol. 2015Mar;230(3):510–25.
28. Adornetto A, Russo R, Parisi V. Neuroinflammation as a target for glaucoma therapy. Vol. 14, Neural Regeneration Research. 2019. p. 391–4.
29. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev [Internet]. 2001 Dec;53(4):527–52. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11734617
30. Saccà SC, Izzotti A. Oxidative stress and glaucoma: injury in the anterior segment of the eye. In 2008. p. 385–407. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0079612308011278
31. Saccà SC, Izzotti A. Oxidative stress and glaucoma: injury in the anterior segment of the eye. In 2008. p. 385–407.
32. Davis BM, Crawley L, Pahlitzsch M, Javaid F, Cordeiro MF. Glaucoma:

the retina and beyond. Acta Neuropathol. 2016;132(6):807–26.
33. Morgan JE. HANDBOOK GLAUCOMA. 8th ed. Philadelphia; 2018. 57–65 p.
34. Jonas JB, Aung T, Bourne RR, Bron AM, Ritch R, Panda-jonas S. Seminar Glaucoma. 2017;390:83–93.
37. Luo X, Shen Y meng, Jiang M nan, Lou X feng, Shen Y. Ocular Blood Flow Autoregulation Mechanisms and Methods. 2015;2015.
38. Schuster AK, Erb C, Hoffmann EM, Dietlein T, Pfeiffer N. The Diagnosis and Treatment of Glaucoma. 2020;
40. Scuderi G, Fragiotta S, Scuderi L, Iodice CM, Perdicchi A. Ganglion cell complex analysis in glaucoma patients: What can it tell us? Eye Brain. 2020;12:33–44.
41. Madeira MH, Boia R, Ambrósio AF, Santiago AR. Having a Coffee Break: The Impact of Caffeine Consumption on Microglia-Mediated Inflammation in Neurodegenerative Diseases. Mediators Inflamm. 2017;2017.
42. Baudouin C, Kolko M, Melik-Parsadaniantz S, Messmer EM. Inflammation in Glaucoma: From the back to the front of the eye, and beyond. Prog Retin Eye Res. 2021;83.
43. Aires ID, Boia R, Rodrigues-Neves AC, Madeira MH, Marques C, Ambrósio AF, et al. Blockade of microglial adenosine A 2A receptor suppresses elevated pressure-induced inflammation, oxidative stress, and cell death in retinal cells. Glia [Internet]. 2019 May 22;67(5):896–914. Available from: https://onlinelibrary.wiley.com/doi/10.1002/glia.23579
44. Madeira MH, Elvas F, Boia R, Gonçalves FQ, Cunha RA, Ambrósio AF, et al. Adenosine A2AR blockade prevents neuroinflammation-induced death of retinal ganglion cells caused by elevated pressure. J Neuroinflammation [Internet]. 2015 Dec 10;12(1):115. Available from: https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-015-0333-5
45. Ruggiero M, Calvello R, Porro C, Messina G, Cianciulli A, Panaro MA. Neurodegenerative Diseases: Can Caffeine Be a Powerful Ally to Weaken Neuroinflammation? Int J Mol Sci. 2022;23(21).
46. Alsabri SG, Mari WO, Younes S, Elsadawi MA, Oroszi TL. Kinetic and Dynamic Description of Caffeine. J Caffeine Adenosine Res. 2018;8(1):3–9.
47. Willson C. The clinical toxicology of caffeine: A review and case study. Toxicol Reports. 2018;5(November):1140–52.
48. Ficarrotta KR, Mohamed YH, Passaglia CL. Experimental glaucoma model with controllable intraocular pressure history. Sci Rep. 2020 Jan;10(1):126.
49. Chen S, Zhang X. The rodent model of glaucoma and its implications. Asia-Pacific J Ophthalmol. 2015;4(4):236–41.
50. Bouhenni RA, Dunmire J, Sewell A, Edward DP. Animal models of glaucoma. J Biomed Biotechnol. 2012;2012(May).
51. Agarwal R, Agarwal P. Rodent models of glaucoma and their applicability for drug discovery. Expert Opin Drug Discov [Internet]. 2017;12(3):261– 70. Available from: http://dx.doi.org/10.1080/17460441.2017.1281244
52. Evangelho K, Mastronardi CA, De-La-Torre A. Experimental models of glaucoma: A powerful translational tool for the future development of new

therapies for glaucoma in humans—A review of the literature. Med. 2019;55(6).
53. Dutta S, Sengupta P. Men and mice: Relating their ages. Life Sci. 2016;152:244–8.
54. Nair A, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7(2):27.
55. Sim RH, Sirasanagandla SR, Das S, Teoh SL. Treatment of Glaucoma withNatural Products and Their Mechanism of Action: An Update. Nutrients [Internet]. 2022 Jan 26;14(3):534. Available from:https://www.mdpi.com/2072-6643/14/3/534
56. Johnson T V, Tomarev SI. Animal Models of Glaucoma. 2016;
57. Trost A, Motloch K, Bruckner D, Schroedl F, Bogner B, Kaser-Eichberger A, et al. Time-dependent retinal ganglion cell loss, microglial activation and blood-retina-barrier tightness in an acute model of ocular hypertension. Exp Eye Res [Internet]. 2015 Jul;136:59–71. Available from: https://linkinghub.elsevier.com/retrieve/pii/S001448351500158X
58. Teister J, Anders F, Beck S, Funke S, Pein H Von, Prokosch V, et al. Decelerated neurodegeneration after intravitreal injection of α - synuclein antibodies in a glaucoma animal model. Sci Rep [Internet]. 2017;(July):1– 16. Available from: http://dx.doi.org/10.1038/s41598-017-06702-1
59. Holve DL, Gum GG, Pritt SL. Effect of Sedation with Xylazine and Ketamine on Intraocular Pressure in New Zealand White Rabbits. 2013;52(4):488–90.
60. Zhang L, Li G, Shi M, Liu HH, Ge S, Ou Y, et al. Establishment and Characterization of an Acute Model of Ocular Hypertension by Laser- Induced Occlusion of Episcleral Veins. Investig Opthalmology Vis Sci. 2017 Aug;58(10):3879.
61. Avisar R, Avisar E, Weinberger D. Effect of Coffee Consumption on Intraocular Pressure. Ann Pharmacother [Internet]. 2002 Jun 28;36(6):992–
5. Available from: http://journals.sagepub.com/doi/10.1345/aph.1A279
62. Varma S, Chandra. Effect of caffeine on the intraocular pressure in patientswith primary open angle glaucoma. Clin Ophthalmol [Internet]. 2011Nov;1623. Available from: http://www.dovepress.com/effect-of-caffeine-on-the-intraocular-pressure-in-patients-with-primar-peer-reviewed-article- OPTH
64. Jiwani AZ, Rhee DJ, Brauner SC, Gardiner MF, Chen TC, Shen LQ, et al. Effects of caffeinated coffee consumption on intraocular pressure, ocular perfusion pressure, and ocular pulse amplitude: a randomized controlled trial. Eye (Lond). 2012 Aug;26(8):1122–30.
65. Ahmed A, Jammal AA, Estrela T, Berchuck SI, Medeiros FA. Intraocular Pressure and Rates of Macular Thinning in Glaucoma. Ophthalmol Glaucoma. 2023;
66. Conti F, Lazzara F, Romano GL, Platania CBM, Drago F, Bucolo C. Caffeine Protects Against Retinal Inflammation. Front Pharmacol. 2021;12:824885.